Alnylam news from FierceBiotech
NewsTakeda and Alnylam - Billion-dollar deals
Who: TakedaWith: Alnylam What: $1 billion licensing deal Scoop: In May, Takeda continued its expansion in the U.S. with a $1 billion move into the RNAi field. In an alliance with RNAi powerhouse Read more...
Novartis extends $700M Alnylam pact
Novartis has extended its pact with Alnylam through October 2009. The deal, which is worth up to $700 million Read more...
Alnylam inks another Japanese development pact
Cambridge, MA-based Alnylam Pharmaceuticals has signed on to a $93 million pact with Japan's Kyowa Hakko Kogyo to develop an Respiratory Syncytial Virus therapy for Asian markets. Alnylam gets $15 Read more...
Takeda gains RNAi tech with $1B Alnylam deal
Takeda's quest to expand in the U.S. market--and off-set expiring patents on big drugs--continues. The Japanese company announced today a $1 billion alliance with RNAi company Alnylam. The deal Read more...
GSK tests the miRNA waters with $600M deal
Further solidifying RNA's "next big thing" status, GlaxoSmithKline and Regulus Read more...
Shares slip as developers see RNAi doubts
Shares of Opko and Alnylam have slid since a new study published in late March concluded that experimental drugs developed with the hot new science of RNA interference may work by activating the Read more...
Alnylam trial shows RNAi works in humans
Alnylam is offering up the first signs that RNAi therapy may work in humans. In a small Phase II trial, Alnylam's Read more...
Alnylam's makes progress with RNAi program
RNAi trailblazer Alnylam has published a paper in the journal Human Molecular Genetics that details RNAi's ability to silence a gene implicated in early onset torsion dystonia. Dystonia is a Read more...
Alnylam gains on positive mid-stage RSV data
Shares of Alnylam surged this morning on the news that mid-stage data for its experimental Read more...
Alnylam, Merck dump RNAi deal
A little more than a year after revising their RNAi development deal to include $120 million in milestone payments, Read more...
| Press ReleasesPRESS RELEASE: Alnylam Pharmaceuticals Announces the Termination of its Collaboration with Merck Alnylam Pharmaceuticals Announces the Termination of its Collaboration with Merck CAMBRIDGE, Mass -- Alnylam Pharmaceuticals, a leading RNAi therapeutics company, announced today that Merck & Read more... PRESS RELEASE: Isis and Alnylam Launch Regulus Therapeutics Isis and Alnylam Launch Regulus Therapeutics, a Joint Venture to Discover, Develop, and Commercialize microRNA Therapeutics - By Targeting Gene Pathways, microRNA Therapeutics Represent a New Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets